| COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study MC Garassino, JG Whisenant, LC Huang, A Trama, V Torri, F Agustoni, ... The Lancet Oncology 21 (7), 914-922, 2020 | 646 | 2020 |
| A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable A Cortellini, M Bersanelli, S Buti, K Cannita, D Santini, F Perrone, R Giusti, ... Journal for immunotherapy of cancer 7, 1-11, 2019 | 331 | 2019 |
| Association of obesity with survival outcomes in patients with cancer: a systematic review and meta-analysis F Petrelli, A Cortellini, A Indini, G Tomasello, M Ghidini, O Nigro, M Salati, ... JAMA Network Open 4 (3), e213520-e213520, 2021 | 249 | 2021 |
| Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice A Cortellini, M Tucci, V Adamo, LS Stucci, A Russo, ET Tanda, ... Journal for immunotherapy of cancer 8 (2), 2020 | 158 | 2020 |
| Clinical outcomes of patients with advanced cancer and pre‐existing autoimmune diseases treated with anti‐programmed death‐1 immunotherapy: a real‐world transverse study A Cortellini, S Buti, D Santini, F Perrone, R Giusti, M Tiseo, M Bersanelli, ... The oncologist 24 (6), e327-e337, 2019 | 152 | 2019 |
| Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: a real‐world study A D’Alessio, CAM Fulgenzi, N Nishida, M Schönlein, J von Felden, ... Hepatology 76 (4), 1000-1012, 2022 | 138 | 2022 |
| Correlations between the immune-related adverse events spectrum and efficacy of anti-PD1 immunotherapy in NSCLC patients A Cortellini, R Chiari, B Ricciuti, G Metro, F Perrone, M Tiseo, M Bersanelli, ... Clinical lung cancer 20 (4), 237-247. e1, 2019 | 136 | 2019 |
| Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective … DJ Pinato, J Tabernero, M Bower, L Scotti, M Patel, E Colomba, S Dolly, ... The Lancet Oncology 22 (12), 1669-1680, 2021 | 108 | 2021 |
| Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/Programmed cell death … A Cortellini, M Bersanelli, D Santini, S Buti, M Tiseo, K Cannita, F Perrone, ... European Journal of Cancer 128, 17-26, 2020 | 95 | 2020 |
| Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab … A Cortellini, M Di Maio, O Nigro, A Leonetti, DL Cortinovis, JGJV Aerts, ... Journal for immunotherapy of cancer 9 (4), 2021 | 93 | 2021 |
| Clinical outcomes and toxic effects of single-agent immune checkpoint inhibitors among patients aged 80 years or older with cancer: a multicenter international cohort study CA Nebhan, A Cortellini, W Ma, T Ganta, H Song, F Ye, R Irlmeier, ... JAMA oncology 7 (12), 1856-1861, 2021 | 85 | 2021 |
| Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and … S Buti, M Bersanelli, F Perrone, M Tiseo, M Tucci, V Adamo, LS Stucci, ... European Journal of Cancer 142, 18-28, 2021 | 85 | 2021 |
| Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study A Cortellini, F Bozzetti, P Palumbo, D Brocco, P Di Marino, N Tinari, ... Scientific reports 10 (1), 1456, 2020 | 77 | 2020 |
| Home care for cancer patients during COVID-19 pandemic: the double triage protocol G Porzio, A Cortellini, E Bruera, L Verna, G Ravoni, F Peris, G Spinelli Journal of pain and symptom management 60 (1), e5-e7, 2020 | 75 | 2020 |
| Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression≥ 50%: a multicenter study with external validation A Cortellini, B Ricciuti, M Tiseo, E Bria, GL Banna, JGJV Aerts, F Barbieri, ... Journal for immunotherapy of cancer 8 (2), 2020 | 75 | 2020 |
| Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges A Leonetti, F Facchinetti, R Minari, A Cortellini, CD Rolfo, E Giovannetti, ... Cellular oncology 42, 261-273, 2019 | 73 | 2019 |
| Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of≥ 50% A Cortellini, M Tiseo, GL Banna, F Cappuzzo, JGJV Aerts, F Barbieri, ... Cancer Immunology, Immunotherapy 69, 2209-2221, 2020 | 68 | 2020 |
| Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non‐small cell lung cancer patients: a “hypothesis‐generator” preliminary report A Cortellini, L Verna, G Porzio, F Bozzetti, P Palumbo, C Masciocchi, ... Thoracic cancer 10 (2), 347-351, 2019 | 66 | 2019 |
| Time-dependent COVID-19 mortality in patients with cancer: an updated analysis of the OnCovid registry DJ Pinato, M Patel, L Scotti, E Colomba, S Dolly, A Loizidou, J Chester, ... JAMA oncology 8 (1), 114-122, 2022 | 65 | 2022 |
| TERAVOLT: thoracic cancers international COVID-19 collaboration JG Whisenant, A Trama, V Torri, A De Toma, G Viscardi, A Cortellini, ... Cancer Cell 37 (6), 742-745, 2020 | 62 | 2020 |
